10 results · 37ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

rezum

FDA UDI
NXTHERA, INC.·00855357006010·Delivery Device Kit for BPH

Rezūm Accessory Kit

FDA UDI
NXTHERA, INC.·00855357006034·

REZUM DELIVERY DEVICE KIT FOR BPH

FDA Adverse Event
Injury ·NXTHERA INC.·Product code KNS·December 21, 2018

REZUM DELIVERY DEVICE KIT FOR BPH

FDA Adverse Event
Injury ·NXTHERA INC.·Product code KNS·December 17, 2018

REZUM DELIVERY DEVICE KIT FOR BPH

FDA Adverse Event
Injury ·NXTHERA INC.·Product code KNS·December 18, 2018

REZUM DELIVERY DEVICE KIT FOR BPH

FDA Adverse Event
Injury ·NXTHERA INC.·Product code KNS·December 17, 2018

REZUM DELIVERY DEVICE KIT FOR BPH

FDA Adverse Event
Injury ·NXTHERA INC.·Product code KNS·December 10, 2018

REZUM DELIVERY DEVICE KIT FOR BPH

FDA Adverse Event
Injury ·NXTHERA INC.·Product code KNS·April 5, 2017

Rezum System, Vapor BPH Ablation System, Model Number D2201-003. NxThera Inc. 7351 Kirkwood Lane Suite 138 Maple Grove, MN 55369 USA. Intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men greater or equal to 50 years of age with a prostate volume greater than or equal to 30cm3 and less than or equal to 80cm3. The Rezum System is also indicated for treatment of prostates with hyperplasia of the central zone and/or a median lobe.

FDA Recall
Terminated ·NXTHERA·Product code KNS·July 28, 2017

Rezum System, Vapor BPH Ablation System, Model Number D2201-003. NxThera Inc. 7351 Kirkwood Lane Suite 138 Maple Grove, MN 55369 USA. Intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men greater or equal to 50 years of age with a prostate volume greater than or equal to 30cm3 and less than or equal to 80cm3. The Rezum System is also indicated for treatment of prostates with hyperplasia of the central zone and/or a median lobe.

FDA Enforcement
Class II ·Terminated·NXTHERA·December 27, 2017